Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma

Atsuhiro Kumabe, Sadatomo Zenda, Atsushi Motegi, Masakatsu Onozawa, Naoki Nakamura, Takashi Kojima, Hiroyuki Daiko, Naoyuki Shigematsu, Tetsuo Akimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)


Background/Aim: We assessed the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) in patients with squamous cell carcinoma of the cervical esophagus. Patients and Methods: We retrospectively analyzed 37 patients treated with definitive CCRT. The patients received radiotherapy at a fraction dose of 2 Gy (total; 60 or 70 Gy) and concurrent chemotherapy. Adjuvant chemotherapy consisted of 1 to 2 cycles of 5-fluorouracil plus cisplatin or nedaplatin. Results: The median follow-up was 119.0 months, the 10-year overall survival, progression-free survival and laryngectomy-free survival rates were 35.6, 19.9 and 30.2% respectively. In the univariate analysis, T stage (T4 vs. T1-3) was the only prognostic factor for PFS. The most common acute toxicity was leukocytopenia (Grade 3; 27%). As for late toxicities, 4 patients (11%) developed Grade 2 or 3 esophageal strictures. Conclusion: The results of this study demonstrated that CCRT yielded satisfactory clinical outcomes with acceptable toxicities.

Original languageEnglish
Pages (from-to)5039-5044
Number of pages6
JournalAnticancer research
Issue number9
Publication statusPublished - 2017 Sep



  • Cervical esophageal carcinoma
  • Chemoradiotherapy
  • Prognostic factor
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this